Medine.co.uk

Mamyzin 269.5mg/Ml Powder And Solvent For Suspension For Injection

AN: 01728/2014

Revised: June 2015



SUMMARY OF PRODUCT CHARACTERISTICS


1. Name of the Veterinary Medicinal Product

Mamyzin 269.5 mg/ml Powder and Solvent for Suspension for Injection


2. Qualitative and Quantitative Composition


Each 5g vial contains:

Penethamate hydriodide 5 million IU

Each 10g vial contains:

Penethamate hydriodide 10 million IU


Each 15ml and 30ml vial of solvent contains:

methyl parahydroxybenzoate, as preservative 1.5mg/ml


Each ml of the reconstituted product contains 269.5 mg of penethamate hydriodide.


For the full list of excipients, see section 6.1


3. Pharmaceutical Form

Powder and solvent for suspension for injection

Powder vial: White to off-white crystalline powder

Solvent vial: Clear solution

4.0 Clinical Particulars

4.1 Target Species


Cattle, dairy


4.2 Indications for use, specifying the target species


Bovine mastitis caused by penicillin sensitive organisms.

4.3 Contraindications


Do not use in animals known to be hypersensitive to penicillin.

Do not administer by intravenous injection.

4.4 Special warnings for each target species

None

4.5 Special Precautions for Use


i) Special precautions for use in animals


Therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.


(ii) Special Precautions to be taken by the person administering the medicinal product to animals


Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross-reactions to cephalosporins and vice versa. Allergic reactions to these substances may occasionally be serious.

Do not handle this product is you know you are sensitised, or if you have been advised not to work with such preparations.

Handle the product with great care to avoid exposure, taking all recommended precautions.

If you develop symptoms following exposure such as a skin rash, you should seek medical advice and show the Doctor this warning. Swelling of the face, lips or eyes or difficulty breathing are more serious symptoms and require urgent medical attention.

Wash hands after use.

In the event of self-injection, seek medical advice.


4.6 Adverse reactions (frequency and seriousness)

In very rare cases anaphylactic shock may occur, which can be fatal.


4.7 Use during Pregnancy, lactation or lay


Can be used during pregnancy.


4.8 Interaction with other medicinal products and other forms of interaction.


Penicillins should not be administered concurrently with bacteriostatic antibiotics.


4.9 Amounts to be administered and administration route


Reconstitution: Reconstitute the suspension using the entire contents of the 5g vial with the 15ml vial of diluent OR the 10g vial with the 30 ml vial of diluent provided.

Use only 5g vial with 15ml diluent and 10g vial with 30ml diluent to provide the correct dose.

Shake well after reconstitution.


Dosage: The dose is 10 – 15 mg penethamate hydriodide per kg bodyweight. This is equivalent to 3.5 – 5.5 ml of the reconstituted suspension per 100 kg bodyweight.

Shake well before administration.


The injection can be repeated with a time interval of 24 hours for up to 4 days in

total.

For intramuscular use. Do not administer intravenously.


4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary


Penicillins have a very wide margin of safety.


4.11 Withdrawal Periods


Animals must not be slaughtered for human consumption during treatment. Milk for human consumption must not be taken from a cow during treatment.


Cattle Meat or Offal: 7 days

Cattle Milk : 108 hours

5 Pharmacological Properties


ATC Vet Code : QJ01CE90 : Beta lactamase sensitive penicillins.


5.1 Pharmacodynamic properties


Its mode of action is by prevention of cell wall synthesis during bacterial cell growth and is primarily bactericidal.The in-vitro spectrum of activity is mainly within the gram-positive class of bacteria eg Staphylococcusspp, Streptococcus spp, Clostridiumspp, Bacillusspp etc.


5.2 Pharmacokinetic properties


Penethamate hydriodide is a prodrug which releases benzylpenicillin quantitatively at hydrolysis. The pKa-value of penethamate hydriodide is 8.4. This means that in aqueous solution at physiological pH of 7.2, 8.2% of the drug will be present as the uncharged molecule while 91.8% will be present as the ion. In aqueous solution penethamate is hydrolysed to form benzylpenicillin and diethylaminoethanol. After intramuscular injection the prodrug itself as well as the released alcohol, diethylaminoethanol has not shown any unexpected pharmacological effects.


6. Pharmaceutical Particulars


6.1 List of excipients

Methyl parahydroxybenzoate

Water for injections

Egg lecithin

Sodium citrate anhydrous

Polysorbate 81


6.2 Incompatibilities


None known.

6.3 Shelf Life,


Shelf-life of the veterinary medicinal product as packaged for sale: 3 years.

Shelf-life after reconstitution according to directions: Use immediately.


6.4 Special Precautions for Storage

Do not store above 25C.

Discard unused suspension.

Keep the container in the outer carton.


6.5 Nature and Contents of Container


Colourless, Type I Ph Eur glass vials, closed with butyl rubber stoppers and

metal caps containing either 5 or 10 g of penethamate hydriodide and 15 or 30 ml solvent to produce a reconstituted suspension.

Pack sizes:

10g vials and 30ml solvent x 10

5g vials and 15ml solvent x 10

Not all pack sizes may be marketed


6.6 Special Precautions for the Disposal of Unused Veterinary Medicinal Product or Waste Materials derived from the use of such products, if appropriate.


Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with national requirements.



7. MARKETING AUTHORISATION HOLDER.

Boehringer Ingelheim Ltd

Ellesfield Avenue

Bracknell

Berkshire

RG12 8YS


8. MARKETING AUTHORISATION NUMBER


Vm 00015/4062

9. DATE OF FIRST AUTHORISATION


Date:15 March 2000


10. DATE OF REVISION OF THE TEXT


Date:June 2015



APPROVED 25/06/15

Page 5 of 5